Skip to main content

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Publication ,  Journal Article
Deininger, MW; Shah, NP; Altman, JK; Berman, E; Bhatia, R; Bhatnagar, B; DeAngelo, DJ; Gotlib, J; Hobbs, G; Maness, L; Mead, M; Metheny, L ...
Published in: J Natl Compr Canc Netw
October 1, 2020

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

October 1, 2020

Volume

18

Issue

10

Start / End Page

1385 / 1415

Location

United States

Related Subject Headings

  • Translocation, Genetic
  • Philadelphia Chromosome
  • Oncology & Carcinogenesis
  • Medical Oncology
  • Leukemia, Myeloid, Chronic-Phase
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Humans
  • Fusion Proteins, bcr-abl
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Deininger, M. W., Shah, N. P., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., … Sundar, H. (2020). Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 18(10), 1385–1415. https://doi.org/10.6004/jnccn.2020.0047
Deininger, Michael W., Neil P. Shah, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Daniel J. DeAngelo, et al. “Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw 18, no. 10 (October 1, 2020): 1385–1415. https://doi.org/10.6004/jnccn.2020.0047.
Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, et al. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Oct 1;18(10):1385–415.
Deininger, Michael W., et al. “Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw, vol. 18, no. 10, Oct. 2020, pp. 1385–415. Pubmed, doi:10.6004/jnccn.2020.0047.
Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, DeAngelo DJ, Gotlib J, Hobbs G, Maness L, Mead M, Metheny L, Mohan S, Moore JO, Naqvi K, Oehler V, Pallera AM, Patnaik M, Pratz K, Pusic I, Rose MG, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Oct 1;18(10):1385–1415.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

October 1, 2020

Volume

18

Issue

10

Start / End Page

1385 / 1415

Location

United States

Related Subject Headings

  • Translocation, Genetic
  • Philadelphia Chromosome
  • Oncology & Carcinogenesis
  • Medical Oncology
  • Leukemia, Myeloid, Chronic-Phase
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Humans
  • Fusion Proteins, bcr-abl
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis